Cervical cancer clinical trials

Seattle Cancer Care Alliance (SCCA) was formed, in part, to bring promising new treatments to patients faster. For cervical cancer patients, this means more treatment options at SCCA than you might find elsewhere, including the chance to participate in one of many ongoing clinical trials conducted at SCCA and its partner organizations, Fred Hutch and UW Medicine.

Below is a list of cervical cancer clinical trials that are currently open and accepting patients at SCCA.
For general information about clinical trials, see the Patient Guide to Clinical Trials.

Displaying 14 of 14 trials

Start new search

A Dose Escalation Study of PF-06939999 in Participants With Advanced or Metastatic Solid Tumors.

A Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Doses of PF-06939999 (PRMT5 Inhibitor) in Participants with Advanced Metastatic Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Esophageal Cancer, Endometrial Cancer, Cervical Cancer and Bladder Cancer

Investigator:

Kaylyn Kit Man M. Wong, MD

Study ID:

NCT03854227

View Trial

Basket Trial in Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3- (FUZE Clinical Trial)

A Phase II basket study of the oral selective pan-FGFR inhibitor Debio 1347 in subjects with solid tumors harboring a fusion of FGFR1, FGFR2 or FGFR3

Investigator:

Petros Grivas, MD, PhD

Study ID:

NCT03834220

View Trial

Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826)

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer

Investigator:

John B. Liao, MD, PhD

Study ID:

NCT03635567

View Trial

A Phase 1, Study Evaluating the Safety, Tolerability, PK, and Efficacy of AMG 510 in Subjects With Solid Tumors With a Specific KRAS Mutation.

A Phase 1, First-in-Human, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 in Subjects With Advanced Solid Tumors with a Specific KRAS Mutation

Investigator:

Andrew Coveler, MD

Study ID:

NCT03600883

View Trial

Phase 1 Study of the Highly-selective RET Inhibitor BLU-667 in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors

A Phase 1 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-small Cell Lung Cancer (NSCLC) and other Advanced Solid Tumors

Investigator:

Christina S. Baik, MD, MPH

Study ID:

NCT03037385

View Trial

A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors

A PHASE IA/IB OPEN-LABEL, DOSE-ESCALATION STUDY OF THE SAFETY AND PHARMACOKINETICS OF RO7198457 AS A SINGLE AGENT AND IN COMBINATION WITH ATEZOLIZUMAB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC TUMORS

Investigator:

Kaylyn Kit Man M. Wong, MD

Study ID:

NCT03289962

View Trial

A Phase I/Ib Study of NIZ985 in Combination With PDR001 in Adults With Metastatic Cancers

A Phase 1/1b Study of Subcutaneous Recombinant Human NIZ985 ((hetIL-15) (IL15/sIL-15-15Ra)) alone and in Combination with PDR001 in Adults with Metastatic Cancers

Investigator:

John A. Thompson, MD

Study ID:

NCT02452268

View Trial

Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides

A Phase 1 Dose Escalation Trial of Intratumoral Injections of TTI-621 in Subjects with Relapsed and Refractory Percutaneously-Accessible Solid Tumors and Mycosis Fungoides

Investigator:

John A. Thompson, MD

Study ID:

NCT02890368

View Trial

A Phase 1 Trial of a Novel XPO1 Inhibitor in Patients With Advanced Solid Tumors

A Phase 1 Study of SL-801, a Reversible Inhibitor of Nuclear Export, in Patients with Advanced Solid Tumors

Investigator:

E. Gabriela Chiorean, MD

Study ID:

NCT02667873

View Trial

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK1/2/3, ROS1, or ALK Gene Rearrangements (Fusions) (STARTRK-2)

An Open-Label, Multicenter, Global Phase II Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Investigator:

E. Gabriela Chiorean, MD

Study ID:

NCT02568267

View Trial

A Study to Investigate the Safety and Efficacy of Nivolumab in Virus-associated Tumors (CheckMate358)

Non-Comparative, Two-Cohort, Single-Arm, Open-Label, Phase 1/2 Study of Nivolumab (BMS-963558) In subjects with Virus-Positive and Virus-Negative Tumors

Investigator:

Shailender Bhatia, MD

Study ID:

NCT02488759

View Trial

Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy

Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or Without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterectomy

Investigator:

Heidi J. Gray, MD

Study ID:

NCT00980954

View Trial

HPV Vaccine Therapy in Interrupting Progression in Patients With High-Grade Vulvar or Anal Lesions

HPV Vaccine to Interrupt Progression of Vulvar and Anal Neoplasia (VIVA) Clinical Trial: A Randomized, Double-Blind, Placebo-Controlled Trial

Investigator:

Anna Wald, MD

Study ID:

NCT03051516

View Trial